LearnGlossaryMarketStocksSuperinvestorsSign in

ATRC

AtriCure, Inc.

Healthcare · $2.9B market cap

Verdict

We can't put a fair value on ATRC right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

2 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth10.1% a year✓
Sales growth15.0% a year✓
Free cash flow growth—?
Return on invested capital-4.3%✗

Follow ATRC

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds ATRC. In Q2 2026, 1 added. Who we track

First Eagle Investment Management

First Eagle Investment Management · as of Q2 2026

$8.3M

297,643 shares

Moves in Q2 2026

Added: First Eagle Investment Management

Insider activity

Since Sep 2, 2026: no open-market purchases and 2 sales worth $609K. Why purchases matter

Sales

Privitera Salvatore

Chief Technical Officer · 2026-09-08

Sold

$201K

Privitera Salvatore

Chief Technical Officer · 2026-09-02

Sold

$408K

About AtriCure, Inc.

AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other international territories. The company's product line features various ablation technologies. These include Isolator Synergy Clamps, which are single-use radiofrequency products. Its multifunctional pens, such as the MAX…

Medical - Instruments & Supplies

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works